Thomas Jefferson University

Karen Tourian

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records and Publicatio - Thomas Jefferson University
Address833 Chestnut Street
Philadelphia PA 19023
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol. 2016 12; 26(10):909-921. PMID: 27428303.
      Citations:    
    2. Clayton AH, Hwang E, Kornstein SG, Tourian KA, Cheng RF, Abraham L, Mele L, Boucher M. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis. Int Clin Psychopharmacol. 2015 Nov; 30(6):307-15. PMID: 26230270.
      Citations:    
    3. Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial. Prim Care Companion CNS Disord. 2015; 17(4). PMID: 26693033.
      Citations:    
    4. Clayton AH, Tourian KA, Focht K, Hwang E, Cheng RF, Thase ME. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015 May; 76(5):562-9. PMID: 25375652.
      Citations:    
    5. Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr; 31(4):809-20. PMID: 25758058.
      Citations:    
    6. Findling RL, Groark J, Chiles D, Ramaker S, Yang L, Tourian KA. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014 May; 24(4):201-9. PMID: 24611442.
      Citations:    
    7. Tourian K, Wang Y, Ii Y. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol. 2013 Jul; 28(4):206-13. PMID: 23587982.
      Citations:    
    8. Liebowitz MR, Tourian KA, Hwang E, Mele L. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013 Mar 22; 13:94. PMID: 23517291.
      Citations:    
    9. Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial. J Clin Psychiatry. 2013 Feb; 74(2):158-66. PMID: 23473348.
      Citations:    
    10. Iwata N, Tourian KA, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 50?mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013 Jan; 19(1):5-14. PMID: 23334675.
      Citations:    
    11. Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2012 Sep; 17(3):121-30. PMID: 22883315.
      Citations:    
    12. Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord. 2011; 13(2). PMID: 21977353.
      Citations:    
    13. Nichols AI, Tourian KA, Tse SY, Paul J. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol. 2010 Dec; 6(12):1565-74. PMID: 21067460.
      Citations:    
    14. Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA. HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Pharmacopsychiatry. 2010 Nov; 43(7):271-6. PMID: 20830664.
      Citations:    
    15. Tourian KA, Padmanabhan K, Groark J, Ninan PT. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. J Clin Psychopharmacol. 2010 Aug; 30(4):411-6. PMID: 20631558.
      Citations:    
    16. Tourian KA, Jiang Q, Ninan PT. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials. CNS Spectr. 2010 Mar; 15(3):187-93. PMID: 20414167.
      Citations:    
    17. Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol. 2010 Feb; 30(1):18-24. PMID: 20075643.
      Citations:    
    18. Liebowitz MR, Tourian KA. Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010; 12(3). PMID: 20944767.
      Citations:    
    19. Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010; 12(1):PCC.08m00746. PMID: 20582292.
      Citations:    
    20. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov; 24(6):296-305. PMID: 19779354.
      Citations:    
    21. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009 Jun; 31 Pt 1:1405-23. PMID: 19698901.
      Citations:    
    22. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009 Apr; 14(4):183-95. PMID: 19407730.
      Citations:    
    23. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr. 2009 Jan; 14(1):41-50. PMID: 19169187.
      Citations:    
    24. Kornstein SG, Fava M, Jiang Q, Tourian KA. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. Psychopharmacol Bull. 2009; 42(3):21-35. PMID: 19752839.
      Citations:    
    25. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008 Sep; 23(5):243-53. PMID: 18703933.
      Citations:    
    26. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, Germain JM, Pitrosky B. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008 Jul; 23(4):188-97. PMID: 18545056.
      Citations:    
    27. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008 Jul; 24(7):1877-90. PMID: 18507895.
      Citations:    
    28. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007 Nov; 22(6):338-47. PMID: 17917552.
      Citations:    
    29. March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007 Nov 15; 62(10):1149-54. PMID: 17553467.
      Citations:    
    30. Kampman K, Majewska MD, Tourian K, Dackis C, Cornish J, Poole S, O'Brien C. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav. 2003 Apr; 28(3):437-48. PMID: 12628617.
      Citations:    
    31. Alterman AI, McKay JR, Mulvaney FD, Cnaan A, Cacciola JS, Tourian KA, Rutherford MJ, Merikle EP. Baseline prediction of 7-month cocaine abstinence for cocaine dependence patients. Drug Alcohol Depend. 2000 Jun 01; 59(3):215-21. PMID: 10812282.
      Citations:    
    32. Tourian K, Alterman A, Metzger D, Rutherford M, Cacciola JS, McKay JR. Validity of three measures of antisociality in predicting HIV risk behaviors in methadone-maintenance patients. Drug Alcohol Depend. 1997 Aug 25; 47(2):99-107. PMID: 9298331.
      Citations:    
    33. Tourian K, Ross D. Panic disorder: a commentary. Md Med J. 1993 Mar; 42(3):307. PMID: 8350694.
      Citations:    
    Tourian's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (98)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _